论文部分内容阅读
目的研究IMPDH2在良性前列腺增生和前列腺癌中的表达,并分析其表达水平与临床病理特征的关系。方法收集临床手术切除的前列腺癌组织和前列腺增生,或者穿刺活检组织,所有组织均由病理学确诊。排除已做手术去势的前列腺组织。通过Western Blot检测IMPDH2在前列腺癌、前列腺增生组织中IMPDH2蛋白的表达情况;免疫组化检测前列腺癌、前列腺增生标本中IMPDH2的表达。分析IMPDH2基因的表达水平与临床病理特征的关系。结果前列腺癌患者组织中IMPDH2蛋白表达显著上调,IMPDH2蛋白表达上调与肿瘤临床分期、Gleason评分、转移相关。结论 IMPDH2在前列腺癌组织中表达上调,前列腺组织中检测IMPDH2可能有助于判断前列腺癌分化程度并评估预后。
Objective To study the expression of IMPDH2 in benign prostatic hyperplasia (BPH) and prostate cancer and analyze its relationship with clinicopathological features. Methods We collected clinically surgically resected prostate cancer, benign prostatic hyperplasia, or biopsy tissue. All tissues were confirmed by pathology. Exclude the surgical castration of prostate tissue. The expression of IMPDH2 protein was detected by Western Blot in prostate cancer and benign prostatic hyperplasia tissues. The expression of IMPDH2 in prostate cancer and benign prostatic hyperplasia was detected by immunohistochemistry. The relationship between IMPDH2 gene expression and clinicopathological features was analyzed. Results The expression of IMPDH2 protein in prostate cancer tissues was significantly up-regulated. The up-regulation of IMPDH2 protein expression was correlated with the clinical stage, Gleason score and metastasis. Conclusion IMPDH2 is up-regulated in prostate cancer tissues. Detection of IMPDH2 in prostate tissue may be helpful in judging the degree of prostate cancer differentiation and assessing the prognosis.